“`html
Terns Pharmaceuticals (NasdaqGS:TERN) has seen its average one-year price target increase by 16.10% to $31.05 per share, up from $26.75 as of November 14, 2025. This new target represents a 5.77% increase over the latest reported closing price of $29.36 per share, with a range of analyst targets between $17.17 and $37.80.
Currently, 272 funds or institutions hold positions in Tern Pharmaceuticals, reflecting a decrease of 3.55% from the previous quarter. Institutional ownership rose by 6.47% in the last three months to 95,206,000 shares, and the put/call ratio stands at 0.28, indicating a bullish outlook.
Soleus Capital Management retains 8,127,000 shares (9.02% ownership), despite a slight decrease from the previous quarter, while Commodore Capital reported an increase to 5,700,000 shares, representing 6.33% ownership. Other significant shareholders include Orbimed Advisors (7,563,000 shares), Deep Track Capital (7,495,000 shares), and Vivo Capital (6,896,000 shares), with no changes in ownership in the last quarter.
“`
